Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma

Keyphrases

• AIDS/HIV 100%
• Pegylated Liposomal Doxorubicin 100%
• Kaposi Sarcoma 100%
• Western Countries 66%
• Tumor 33%
• Quality of Life 33%
• Treatment Choice 33%
• Developing Countries 33%
• Neutropenia 33%
• Cytotoxic Agents 33%
• Hepatotoxicity 33%
• Antiretroviral Therapy 33%
• High Efficacy 33%
• HHV-8 33%
• Cardiotoxicity 33%
• Vascular Tumor 33%
• Skin Toxicity 33%
• Leukopenia 33%
• Kaposi's Sarcoma-associated Herpesvirus 33%
• Virus Pandemic 33%
• Mucositis 33%

INIS

• humans 100%
• safety 100%
• viruses 100%
• doxorubicin 100%
• sarcomas 100%
• drugs 50%
• tumors 50%
• cost 25%
• quality of life 25%
• patients 25%
• toxicity 25%
• skin 25%
• side effects 25%
• developing countries 25%
• combined therapy 25%
• leukopenia 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Kaposi Sarcoma 100%
• Leukopenia 33%